|
We are thrilled to share exciting new clinical data supporting the effectiveness of T2 Biosystems sepsis panels, as presented at the recent European Society of Clinical Microbiology and Infectious Diseases' ESCMID Global conference in Barcelona, Spain.
 |
 |
Key Highlights from ESCMID Global
Improved Patient Outcomes with T2Candida: Clinical outcomes analysis showed that patients diagnosed with T2Candida had a significantly higher probability of achieving better outcomes compared to conventional blood culture testing. This included fewer treatment failures, persistent candidemia, and infectious complications.1
Stewardship-guided T2MR Testing: Data presented by Dr. Tamara Clodi-Seitz demonstrated the prognostic role and clinical implications of culture-independent systems in patients with bloodstream infections. T2Bacteria identified persistent infections longer than blood culture, enabling earlier targeted therapy.2
T2Candida Identifies More Candida Species: A literature review across multiple studies found that T2Candida identified 3.5 times more infections compared to conventional blood culture, with significantly faster turnaround times.3
Real-world Use of T2Resistance Panel: Dr. Oscar Guzman, Vice President of Medical Affairs at T2 Biosystems presented findings from a recent publication in the Journal of Clinical Microbiology, highlighting the effectiveness of the T2Resistance Panel in detecting resistance genes in bacterial bloodstream infections. Results were available much faster compared to blood culture-based methods, leading to a change in therapy for a significant portion of patients.
|
